Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | STK17B | O94768 | 1/20 | 0.31 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17390198 | 0.83 | MEN1 (0.35) | CA12CA1CA2CA9CA14 | |
| SCHEMBL27223302 | 0.82 | — | — | |
| SCHEMBL31573374 | 0.82 | TKT (0.32) | — | |
| SCHEMBL31260800 | 0.81 | DUT (0.33) | CA12CA1CA2CA9CA14 | |
| SCHEMBL30961378 | 0.78 | MAPKAPK2 (0.33) | STK17BSTK17A | |
| SCHEMBL17581324 | 0.78 | MAPKAPK2 (0.33) | STK17BSTK17A | |
| SCHEMBL19219151 | 0.76 | LMNA (0.31) | CA12CA1CA2CA9CA14 | |
| SCHEMBL16796160 | 0.75 | LMNA (0.46) | — | |
| SCHEMBL1243597 | 0.75 | BACE1 (0.34) | BACE1 | |
| SCHEMBL25815965 | 0.75 | ALDH1A1 (0.34) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760763-B2 | Heteroaryl compounds useful as MK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760763-B2 | Heteroaryl compounds useful as MK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760763-B2 | Heteroaryl compounds useful as MK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220064183-A1 | HETEROARYL COMPOUNDS USEFUL AS MK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2022-03-03 | — | — | US | disclosed |
| US-11124525-B2 | Heteroaryl compounds useful as MK2 inhibitors | CELGENE CAR LLC (BM) | 2021-09-21 | — | — | US | disclosed |
| US-11124525-B2 | Heteroaryl compounds useful as MK2 inhibitors | CELGENE CAR LLC (BM) | 2021-09-21 | — | — | US | disclosed |
| US-20200102325-A1 | HETEROARYL COMPOUNDS USEFUL AS MK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2020-04-02 | — | — | US | disclosed |
| WO-2018170200-A1 | HETEROARYL COMPOUNDS USEFUL AS MK2 INHIBITORS | CELGENE CAR LLC (BM) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124525-B2 | Heteroaryl compounds useful as MK2 inhibitors | MKNK2, MKRN3, MKNK1 | CA12 4284/4885CA1 4662/4885CA2 3480/4885 |
| US-20200102325-A1 | HETEROARYL COMPOUNDS USEFUL AS MK2 INHIBITORS | MKNK2, MKRN3, MKNK1 | CA12 4284/4885CA1 4662/4885CA2 3480/4885 |
| US-20220064183-A1 | HETEROARYL COMPOUNDS USEFUL AS MK2 INHIBITORS | MKNK2, MKRN3, MKNK1 | CA12 4284/4885CA1 4662/4885CA2 3480/4885 |
| US-11760763-B2 | Heteroaryl compounds useful as MK2 inhibitors | MKNK2, MKRN3, MKNK1 | CA12 4284/4885CA1 4662/4885CA2 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.